Compare TSE & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSE | NXL |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 18.6M |
| IPO Year | 2014 | 2022 |
| Metric | TSE | NXL |
|---|---|---|
| Price | $0.46 | $0.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 1.6M | 185.1K |
| Earning Date | 02-11-2026 | 03-13-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,133,800,000.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | $4.11 | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $0.54 |
| 52 Week High | $5.99 | $3.87 |
| Indicator | TSE | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 37.58 |
| Support Level | $0.44 | $0.61 |
| Resistance Level | $0.95 | $0.77 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 3.86 | 29.14 |
Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.